Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane

Fig. 1

SH3BGRL is related and binds to HER2 via α2 helix and β3 sheet. a SH3BGRL expression in invasive ductal carcinoma (IDC), compared to their adjacent normal tissues. Results were analyzed based on the gene microarray dataset, GSE15852. b SH3BGRL expression in various types of breast cancers, compared to the normal tissues. Results were analyzed based on the microarray dataset of breast cancer, GSE45827. c Interaction between exogenous SH3BGRL and HER2. GFP-SH3BGRL or control vector and YFP-HER2 plasmids were co-transfected into HEK 293 T cells, and then immunoprecipitation (IP) and immunoblotting (IB) were performed with anti-HER2 antibodies. d Interaction of endogenous SH3BGRL with HER2 determined by Co-IP analyses in MDA-MB-453 cells. e Schematic SH3BGRL truncation mutants based on its structure domains. f Co-IP of the HA-SH3BGRL truncation mutants and YFP-HER2. Cells were co-transfected in HEK 293 T cells, and SH3BGRL and HER2 were respectively immunoprecipitated with anti-HA or anti-HER2 antibodies. g Confocal analysis of the co-localization of HER2 and endogenous SH3BGRL in MDA-MB-453 cells. Cells were stained with SH3BGRL (yellow), HER2 antibody (red) and merged images are shown on the right

Back to article page